Zai Lab (NASDAQ:ZLAB) CEO Ying Du Sells 5,576 Shares of Stock

Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) CEO Ying Du sold 5,576 shares of the business’s stock in a transaction dated Thursday, April 2nd. The shares were sold at an average price of $20.39, for a total transaction of $113,694.64. Following the completion of the transaction, the chief executive officer directly owned 1,125,279 shares of the company’s stock, valued at $22,944,438.81. The trade was a 0.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Zai Lab Price Performance

Zai Lab stock opened at $20.41 on Friday. The stock has a market capitalization of $2.30 billion, a P/E ratio of -12.68 and a beta of 0.86. Zai Lab Limited Unsponsored ADR has a 12-month low of $15.96 and a 12-month high of $44.34. The firm’s 50-day moving average is $18.67 and its two-hundred day moving average is $21.83.

Zai Lab (NASDAQ:ZLAB) last posted its quarterly earnings data on Saturday, February 14th. The company reported ($0.50) earnings per share for the quarter. Zai Lab had a negative net margin of 38.15% and a negative return on equity of 22.81%. The firm had revenue of $127.60 million during the quarter. As a group, analysts forecast that Zai Lab Limited Unsponsored ADR will post -2.58 EPS for the current year.

Hedge Funds Weigh In On Zai Lab

A hedge fund recently bought a new stake in Zai Lab stock. SG Americas Securities LLC bought a new stake in shares of Zai Lab Limited Unsponsored ADR (NASDAQ:ZLAB) during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 9,754 shares of the company’s stock, valued at approximately $331,000. Institutional investors own 41.65% of the company’s stock.

Wall Street Analyst Weigh In

ZLAB has been the topic of several recent analyst reports. Zacks Research downgraded Zai Lab from a “hold” rating to a “strong sell” rating in a research report on Friday, January 23rd. UBS Group initiated coverage on shares of Zai Lab in a research note on Wednesday, January 7th. They set a “buy” rating and a $35.00 price objective for the company. Jefferies Financial Group upgraded shares of Zai Lab to a “strong-buy” rating in a report on Monday, January 19th. JPMorgan Chase & Co. decreased their target price on shares of Zai Lab from $39.00 to $32.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 18th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Zai Lab in a report on Wednesday, January 21st. One investment analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $50.00.

Zai Lab Company Profile

Zai Lab Ltd (NASDAQ: ZLAB) is a biopharmaceutical company focused on the research, development, manufacturing and commercialization of innovative therapies. Headquartered in Shanghai, China, Zai Lab operates R&D centers in Asia and the United States and maintains commercial offices across Greater China, North America, Europe and Australia. The company’s end-to-end platform encompasses discovery biology, translational development, clinical research and global supply chain management.

The company’s marketed portfolio is anchored by Brukinsa (zanubrutinib), a next-generation Bruton’s tyrosine kinase inhibitor approved for several B-cell malignancies.